This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Quality of Life  • Osteoporosis  • Prostate Disease  • Oncology  • Prostate Cancer  • Adverse Effects  • Alert me on articles by topic

M. J. Friedrich

JAMA. 2006;296:2305-2306.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Boston—Because prostate cancer growth is fueled by androgens—especially testosterone—androgen deprivation therapy (ADT) is the treatment of choice for the 40% of men with this cancer who have disease that has spread beyond the prostate, a condition not amenable to surgical cure. While ADT achieves temporary symptom relief and tumor control in up to 80% of cases, this comes at a cost, said Laurence Katznelson, MD, associate professor of medicine and neurosurgery at Stanford University School of Medicine, Palo Alto, Calif.

Depriving the body of androgens is associated with signs and symptoms of male hypogonadism, which include bone loss, changes in body composition, sexual adverse effects, and decline in cognitive function. At the annual Endocrine Society meeting here in June, experts discussed the adverse effects associated with ADT and some of the strategies to counter them.

Androgen deprivation therapy can provide temporary symptom relief and tumor control . . . [Full Text of this Article]

PRESERVING BONE

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

"No Turning Bax" in the Combined Battle against Prostate Cancer:
Rajendran and Kao
Clin. Cancer Res. 2007;13:3435-3438.
FULL TEXT